Immunopathophysiologic basis of multiple sclerosis and implications for therapy-a narrative review

J S Redfern

doi:10.15406/ppij.2021.09.00355

Abstract

Immunopathophysiologic basis of multiple sclerosis and implications for therapy-a narrative review

Highlights

Jean-Martin Charcot, a French neurologist at the Hôpital de Salpétrière, Paris, France, is credited with the first clinical description of multiple sclerosis (MS) in 1868, a disease he termed “la sclérose en plaques.”[1]
The past few decades have led to the development of a plethora of different types of disease-modifying drugs (DMDs) with mechanisms of action directed at various points along MS immunopathophysiologic disease continuum
The results suggested that the effects of cladribine action may, in part, result from a depletion of memory B cells for at least 12 months, a moderate decrease across T cell subtypes, and a recovery over baseline for regulatory B cells, effects that occur without persistent immunosuppression.[46]

Summary

Introduction

Jean-Martin Charcot, a French neurologist at the Hôpital de Salpétrière, Paris, France, is credited with the first clinical description of multiple sclerosis (MS) in 1868, a disease he termed “la sclérose en plaques.”[1].

Results

Conclusion